BMP Sunstone — Investor Presentation (June 2008)
26 slides from BMP Sunstone's investor presentation, Jun 25, 2008
Slide 1: Investor Presentation June 2008
Investor Presentation June 2008
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements convey our current expectations or forecasts of future events. All statements other than statements of histor
Slide 3: Corporate Mission & Vision
3 Mission: To contribute to the improvement of the overall health and welfare of the people of China, and provide access to the highest quality medicine and healthcare products Vision: BMP Sunstone is a fully integrated specialty pharmaceutical company focused on the commercialization of branded pre
Slide 4: Corporate Snapshot
4 US headquarters in Plymouth Meeting, Pennsylvania China headquarters in Beijing Over 1,300 employees Major Subsidiaries: Sunstone Pharma: R&D, manufacturing, sales& marketing for branded OTC products BMP China: Commercialization of Rx products exclusively licensed from MNCs Distribution: Top 3 met
Slide 5: Corporate History
5 Chinese company started ? Abacus (Bermuda-based Investment Fund) acquired 60% of shares ? Abacus acquired remaining 40% of shares ? Reverse merger - US Public Co. & PIPE ? Acquired Wanwei, licensed 2 products & PIPE ? NASDAQ, licensed 1 product & PIPE ? Transformation from a privately held commiss
Slide 6: The Opportunity in Our Target Market
6 Today: China is 7th largest and fastest growing pharmaceutical market in the world Tomorrow: China will be the 5th largest by 2010 and the largest by 2050 Source: IMS Health The Opportunity in Our Target Market
Slide 7: Distinct Pharma Distribution Channels
7 Source: Wall Street Journal Distinct Pharma Distribution Channels In the U.S., 15% of pharmaceutical sales move through hospitals (85% go through retail pharmacies & direct mail) In China, 80% of pharmaceutical sales move through hospitals (only 20% go through retail pharmacies) 85% 15% 20% 80%
Slide 8: Chinese Pharma Distribution Channels
8 DISTRIBUTORS ~7,000 Sales & Marketing Distribution PHARMA MANUFACTURERS ~4,000 HOSPITAL PHARMACISTS 1,500 Class A 3,000 Class B 10,500 Class C 15,000 Clinics Tender Negotiation Formulary Request PHYSICIANS Source: China Pharmaceutical Association Chinese Pharma Distribution Channels RETAIL PHARMAC
Slide 9: BMP Sunstone Solution
9 BMP Sunstone Solution *Expected to close 2H 2008
Slide 10: Sunstone Pharma
10 Company Profile Headquarters: Tangshan, Hebei Province Strong financial results and profitability in 2007 : Revenue of over $42.0 million Net income of $7.3 million Three nationally recognized brand families "GoodBaby(r)" - Certified Famous Chinese Brand / Pediatric OTC Granules, Chewables, Syrup
Slide 11: The Sunstone Premium: Brand Recognition
The Sunstone Premium: Brand Recognition Supplement for Women (8 Products) Women's Health (4 Products) Pediatrics (14 Products) 11
Slide 12: Sunstone Pharma Coverage
Sunstone Pharma Coverage Sales force: 300 Agents: 800 Pharmacies: 50,000 12
Slide 13: BMP China - Gateway to the Chinese Market
BMP China -Gateway to the Chinese Market Exclusive licensing of premium Rx products in niche markets Proprietary prescription product portfolio initially focused on women's health and pediatrics Extensive sales and marketing experience to support high margin business model Support for commercializat
Slide 14: Enhanced Product Portfolio
14 Enhanced Product Portfolio
Slide 15: Product Launch Timeline
Product Launch Timeline *Additional product licensing discussions are ongoing 15 Obstetric Gynecology Oncology Urology 2006 2007 2008 2009 2010 2011 Product Propess Anpo Galake Ondanstron Clindesse Ferriprox Enablex Others 2+ Products under negotiation Dotted lines indicate registration period, diam
Slide 16: BMP China: Proven Track Record
Our fully-integrated approach significantly improved sales volume immediately. Propess? Anpo ? BMP China: Proven Track Record BMP China: Proven Track Record Units 2004 2005 2006 2007 2008 2005 2006 2007 2008 BMP Took Over BMP Took Over 16
Slide 17: Single National Distribution Platform
17 BMP Sunstone is integrating distribution capabilities in Beijing, Shanghai and Guangzhou through select acquisitions and a JV investment. Beijing: Wanwei (2005) > 85 employees (including 30 sales reps) > Relationships with all top-tier Beijing hospitals > Relationships with 120 distributors > 400
Slide 18: Growth Strategy
Expand product portfolio We anticipate launching at least six new licensed products by 2011, or approximately two per year Continue to license drugs from leading pharmaceutical companies Acquisition of compelling product portfolios, both RX and OTC Therapeutic focus on women's health & pediatrics Ad
Slide 19: Senior Management and Board of Directors
19 Senior Management Board of Directors Name Position Experience Fred Powell David (Xiao Ying) Gao Chief Financial Officer Chief Executive Officer, Director VP and GM for Motorola in China/Asia Pacific Region Initiated Chinese business in 1989 (grew to $5.4bn in sales in 2002) Held Senior Positions
Slide 20: Financial Snapshot
20 Financial Snapshot First Quarter 2008 Revenue increased to $18.1 million from $5.7 million in 1Q07 Gross profit increased to $7.7 million with gross margin of 42.7% vs. 11.5% in 2007 Adjusted EBITDA improved to $1.5 million from a loss of $1.4 million in 1Q07 Operating loss improved to $1.4 milli
Slide 21: Financial Performance
21 171.7% CAGR from 2005 to 2007 Reported revenue in the full year 2007 increased 28% to $31.0 million Excludes any revenue from the 49% ownership of Sunstone Revenue in first quarter 2008 increased to $18.1 million, which includes revenue from Sunstone Financial Performance CAGR = 171.7%
Slide 22: Revenue Mix Shift Drives Profitability
22 Pie chart reflects pro forma twelve months through March 31, 2008 OTC business reflects Sunstone acquisition Operating and net margins increase significantly as revenue mix changes Distribution alone becomes smaller percentage of overall business Sunstone's OTC presence creates sales opportunitie
Slide 23: Recent Achievements
23 Sunstone acquisition completed and name changed MOFCOM approval received for Rongheng acquisition Alliance BMP completed GPC joint venture Partnered with leading multinational pharmaceutical and distribution companies such as Novartis and Apotex BMP Sunstone included in NASDAQ Biotech Index Enhan
Slide 24: Goals
Execution of successful integration Optimize national distribution networks Realize cross-selling opportunities between Rx and OTC products Optimizing product portfolio Sunstone: Expand product portfolio over the next three years BMP China: Launch 2 licensed products per year Distribution: Optimize
Slide 25: BMP Sunstone
AV BMP Sunstone NASDAQ:BJGP
Slide 26: 1Q08 Adjusted EBITDA Reconciliation
26 1Q08 Adjusted EBITDA Reconciliation 1Q08 1Q07 Adjusted EBITDA $1,523 ($1,413) Adjustment FAS 123R $563 $316 EBITDA $960 ($1,729) EBITDA Reconciliation to GAAP Net Loss Interest Income ($48) ($150) Interest Expense $802 $19 Income Taxes $347 - -- Depreciation $257 $26 Amortization of intangibles a